Two Leading Mount Sinai Brain Scientists Elected to the National Academy of Sciences
Highest honor recognizing outstanding contributions to science
Yasmin Hurd, PhD, Ward Coleman Chair of Translational Neuroscience and Director of the Addiction Institute of Mount Sinai, and Helen S. Mayberg, MD, founding Director of the Nash Family Center for Advanced Circuit Therapeutics at Mount Sinai, have been elected to the National Academy of Sciences (NAS). Election to the NAS is considered one of the highest honors that a scientist can achieve, recognizing individuals for their distinguished and continuing achievements in original research.
“The recognitions of Dr. Hurd and Dr. Mayberg are well-deserved for the extraordinary contributions each has made to the biomedical sciences,” said Eric J. Nestler, MD, PhD, Nash Family Professor of Neuroscience, Director of The Friedman Brain Institute, and Dean for Academic Affairs for Icahn Mount Sinai, and Chief Scientific Officer for the Mount Sinai Health System. “Dr. Hurd’s work to uncover the neurobiology of drug use has had a major impact on our understanding of addiction and related psychiatric disorders. Likewise, Dr. Mayberg’s identification of novel brain circuits implicated in depression has helped rethink the way we study underlying brain mechanisms, catalyzing a fundamental shift that challenges traditional approaches to treatment.”
Dr. Hurd is an internationally-renowned neuroscientist whose translational research examines the neurobiology of drug addiction and related psychiatric disorders. Her research exploring the neurobiological effects of cannabis and heroin has significantly shaped the field. Using multidisciplinary approaches, her research has provided unique insights into the impact of prenatal and adolescent cannabis exposure on human development and the epigenetic mechanisms underlying the drugs’ effects into adulthood and even across generations.
Her basic science research is complemented by clinical laboratory investigations evaluating the therapeutic potential of novel, science-based strategies for the treatment of opioid addiction, including pioneering work with cannabidiol, a non-intoxicating cannabinoid. Utilizing a truly translational approach, Dr. Hurd and her research team examine molecular and neurochemical events in the human brain and comparable animal models to find neurobiological correlates of behavior. They also conduct neuroimaging studies and human clinical trials to further understand the neurobiology of addiction towards the development of novel therapies. The significant impact of Dr. Hurd’s research is also reflected by its reach into the mainstream media and governmental policies.
Dr. Mayberg is a renowned behavioral neurologist who has established an international reputation for her pioneering research to map the brain circuits implicated in depression and for leading the first studies of deep brain stimulation for treatment-resistant depression, heralded as one of the first hypothesis-driven treatment strategies for a major mental illness. Early in her career, she developed one of the first “network” models for mood disorders, which incorporated the fundamentals of neuroanatomy and brain connections with imaging technologies to propose an alternative neurological view of this classical psychiatric condition that extended beyond the neurochemical models that had dominated for decades. The circuit approach has evolved over the years through collaborations with neuroscientists, clinicians, and engineers.
This approach continues to anchor many contemporary studies of mood disorders, including the identification of clinically meaningful biomarkers that can optimize treatment selection for individual depressed patients at all stages of illness and the development and latest refinements of deep brain stimulation, an experimental procedure for the most severe forms of treatment-resistant depression. Under Dr. Mayberg’s leadership, The Center for Advanced Circuit Therapeutics at Mount Sinai is advancing precision surgical treatments for several neuropsychiatric conditions through the rapid conversion of neuroscience and neuroengineering innovations that correct brain circuit abnormalities to restore mood as well as motor and cognitive functioning.
“Dr. Hurd and Dr. Mayberg stand at the forefront of their fields, leading their contemporaries and others coming up in the field to challenge existing limitations of science and medicine,” said Dennis S. Charney, MD, the Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai, and President for Academic Affairs, Mount Sinai Health System. “Their exemplary work—under the auspices of The Friedman Brain Institute—is a reflection of Mount Sinai’s culture of innovation and our passion to relentlessly push the boundaries of knowledge to help create and discover new treatments that were never before thought possible. We applaud and commend them for their work and for this well-deserved recognition.”
Mount Sinai now has six current faculty members in the National Academy of Sciences, including: Adolfo García-Sastre, PhD, Professor of Microbiology, Medicine (Infectious Diseases) and Pathology, Molecular, and Cell-Based Medicine, and Director of the Global Health and Emerging Pathogens Institute; Maria Iandolo New, MD, Professor of Pediatrics, Medicine (Endocrinology), and Genetic and Genomic Sciences; Peter Palese, PhD, Horace W. Goldsmith Professor and Chair of Microbiology, and Professor of Medicine (Infectious Diseases); and Miriam Merad, MD, PhD, Professor of Oncological Sciences and Medicine (Hematology and Medical Oncology), and Director of the Precision Immunology Institute.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in several pediatric specialties.